Verekitug is under clinical development by Upstream Bio and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Verekitug’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Verekitug is under development for the treatment of severe asthma, chronic rhinosinusitis with nasal polyps and TSLP-mediated inflammation. The drug candidate is administered through parenteral and subcutaneous route. It acts by targeting TSLP.
Upstream Bio overview
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. Upstream Bio is headquartered in Waltham, Massachusetts, the US.
For a complete picture of Verekitug’s drug-specific PTSR and LoA scores, buy the report here.